CStone Pharmaceuticals' stock surged 5.51% during intraday trading on Friday, following the release of its 2025 annual results which highlighted significant strategic and clinical advancements.

The company's detailed earnings report pointed to a pivotal strategic inflection point, with rapid progress across its core R&D pipeline. Key asset CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, showed compelling efficacy data, including a 90% objective response rate in first-line NSCLC patients with high PD-L1 expression. Furthermore, the company successfully expanded the global commercialization footprint of its anti-PD-L1 antibody sugemalimab to over 60 countries and secured important National Reimbursement Drug List (NRDL) inclusions and renewals for its commercial products in China, setting the stage for future revenue growth.

Despite reporting an annual loss, which the company attributed primarily to one-time costs related to preparing pralsetinib for NRDL negotiation, CStone emphasized its solid financial position with cash reserves of RMB918.7 million. Management expressed confidence in the anticipated revenue ramp-up from 2026 onwards and outlined plans to initiate global Phase III trials for CS2009 by the end of the year, reinforcing investor optimism about the company's long-term prospects.